Distinct Histopathologic Patterns of Finger Eruptions in Dermatomyositis Based on Myositis-Specific Autoantibody Profiles

Abstract

patients were male; the majority (10; 67%) were non-Hispanic white with mean age 53 years. Six of the 9 participants who enrolled for 4 weeks continued for 12 weeks. There was no difference in the mean percent change in GLI1 mRNA levels between itraconazole and placebo groups at 4 weeks (132% vs 19.0% from baseline; P = .20). There was no statistically significant difference in the percent change in tumor area between itraconazole and placebo at 4 weeks (0.04% vs -10.9% from baseline; P = .40) and 12 weeks (8.9% vs 26.5%; P = .40). In post hoc analysis, the itraconazole group showed reduced BCC tumor area in the subgroup of BCCs located on the back; however, given multiple testing for different anatomic locations, this difference was ultimately not statistically significant. Using liquid chromatography-mass spectrometry, intratumor itraconazole concentration was 133 g/g of skin at 4 weeks and 96 g/g at 12 weeks. There was no association between change in BCC tumor area and GLI1 mRNA levels. Other major metabolites such as hydroxy-itraconazole were not measured given their weaker half maximal inhibitory concentrations (IC 50 ).